Business
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
CARLSBAD, Calif., May 01, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/b843e18a2873db0c71c8e530c8f909b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kOhox8Ch5RvO8YSDT9HDqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b843e18a2873db0c71c8e530c8f909b9","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sZ.vAoI8JqshegEpmgS.nA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b843e18a2873db0c71c8e530c8f909b9","width":1200,"height":248}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., May 01, 2025--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update.","length":632,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast","length":27,"tagName":"p"},{"type":"text","content":"Interested parties may access the conference call on May 13, 2025, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through May 20, 2025, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1789489.","length":526,"tagName":"p"},{"type":"text","content":"About Lineage Cell Therapeutics, Inc.","length":37,"tagName":"p"},{"type":"text","content":"Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, "off-the-shelf," cell therapies to address unmet medical needs. Lineage’s programs are...